ELAVL1

Summary

ELAVL1 (ELAV like RNA binding protein 1, HGNC:3312) is a protein-coding gene on chromosome 19p13.2, encoding ELAV-like protein 1 (Q15717). RNA-binding protein that binds to the 3’-UTR region of mRNAs and increases their stability. It is a selective cancer dependency (DepMap: 15.4% of cell lines).

The protein encoded by this gene is a member of the ELAVL family of RNA-binding proteins that contain several RNA recognition motifs, and selectively bind AU-rich elements (AREs) found in the 3’ untranslated regions of mRNAs. AREs signal degradation of mRNAs as a means to regulate gene expression, thus by binding AREs, the ELAVL family of proteins play a role in stabilizing ARE-containing mRNAs. This gene has been implicated in a variety of biological processes and has been linked to a number of diseases, including cancer. It is highly expressed in many cancers, and could be potentially useful in cancer diagnosis, prognosis, and therapy.

Source: NCBI Gene 1994 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 24 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 15.4% of screened cell lines
• MANE Select transcript: NM_001419

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3312
Approved symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	HuR, Hua, MelG
Ensembl gene	ENSG00000066044
Ensembl biotype	protein_coding
OMIM	603466
Entrez	1994

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 16 protein_coding, 1 retained_intron

ENST00000407627, ENST00000593807, ENST00000595499, ENST00000596154, ENST00000596459, ENST00000883214, ENST00000883215, ENST00000883216, ENST00000883217, ENST00000883218, ENST00000883219, ENST00000883220, ENST00000934544, ENST00000934545, ENST00000934546, ENST00000958865, ENST00000958866

RefSeq mRNA: 1 — MANE Select: NM_001419 NM_001419

CCDS: CCDS12193

Canonical transcript exons

ENST00000407627 — 6 exons

Exon	Start	End
ENSE00000671649	7967565	7967790
ENSE00000671651	7981083	7981186
ENSE00000954105	7973725	7973878
ENSE00001546985	7958573	7963807
ENSE00003119786	8005495	8005641
ENSE00003593446	7991644	7991831

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 98.06.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.0343 / max 159.1385, expressed in 1814 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178927	23.7486	1814
178925	0.2857	119

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	98.06	gold quality
secondary oocyte	CL:0000655	97.88	gold quality
oocyte	CL:0000023	96.34	gold quality
pericardium	UBERON:0002407	95.87	gold quality
mucosa of sigmoid colon	UBERON:0004993	95.81	gold quality
ventricular zone	UBERON:0003053	95.54	gold quality
corpus epididymis	UBERON:0004359	95.45	gold quality
periodontal ligament	UBERON:0008266	95.42	gold quality
renal medulla	UBERON:0000362	95.28	gold quality
parotid gland	UBERON:0001831	95.25	gold quality
colonic mucosa	UBERON:0000317	95.21	gold quality
caput epididymis	UBERON:0004358	95.15	gold quality
palpebral conjunctiva	UBERON:0001812	94.98	gold quality
cauda epididymis	UBERON:0004360	94.96	gold quality
pharyngeal mucosa	UBERON:0000355	94.93	gold quality
urethra	UBERON:0000057	94.70	gold quality
embryo	UBERON:0000922	94.66	gold quality
seminal vesicle	UBERON:0000998	94.66	gold quality
choroid plexus epithelium	UBERON:0003911	94.66	gold quality
mucosa of paranasal sinus	UBERON:0005030	94.32	gold quality
superficial temporal artery	UBERON:0001614	94.31	gold quality
adult organism	UBERON:0007023	94.23	gold quality
heart right ventricle	UBERON:0002080	94.19	gold quality
cardia of stomach	UBERON:0001162	94.11	gold quality
esophagus squamous epithelium	UBERON:0006920	94.04	gold quality
epithelium of esophagus	UBERON:0001976	94.03	gold quality
mammary duct	UBERON:0001765	94.01	gold quality
body of tongue	UBERON:0011876	93.80	gold quality
cartilage tissue	UBERON:0002418	93.72	gold quality
trabecular bone tissue	UBERON:0002483	93.71	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.73

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
LRP6	Activation

Upstream regulators (CollecTRI, top): ATF2, CDK1, MYC, NFKB, RELA, SMAD1, SP1, SSRP1, TGIF1, TP53, ZFP36

miRNA regulators (miRDB)

292 targeting ELAVL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692A	100.00	74.40	6850
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-551B-5P	99.96	71.28	3493

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 15.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• role in c-fos mRNA export (PMID:11729309)
• A 40-bp RNA element that mediates stabilization of vascular endothelial growth factor mRNA by HuR. (HuR RNA binding protein) (PMID:11834731)
• Results show that AMP-activated kinase (AMPK), an enzyme involved in responding to metabolic stresses, potently regulates the levels of cytoplasmic HuR. (PMID:11971974)
• The binding of HuR, CP1, and CP2 to AR mRNA suggests a role for each of these proteins in the post-transcriptional regulation of AR expression in cancer cells. (PMID:12011088)
• Data show that the RNA-binding protein HuR is specifically methylated on Arg(217) by coactivator-associated arginine methyltransferase 1 (CARM1). (PMID:12237300)
• Highly selective actions of HuR in antagonizing AU-rich element-mediated mRNA destabilization. (PMID:12242302)
• p21(WAF1) protein expression is mediated by stabilization of p21(WAF1) mRNA elicited via multiple 3’-UTR cis-elements. HuR binds at least one of these elements, does not appear to be a modulator of p21(WAF1) expression or growth inhibition in this system (PMID:12431987)
• AMP-activated protein kinase activation can cause premature fibroblast senescence through mechanisms that likely involve reduced HuR function. (PMID:12730239)
• The 3’ UTR of p53 was found to be a target of the RNA-binding protein HuR in a UVC-dependent manner in vitro and in vivo. HuR plays a role in binding to the p53 mRNA and enhancing its translation (PMID:12821781)
• HADHB, HuR, and CP1 are novel REN mRNA-binding proteins that target a cis-element in the 3’-UTR of REN mRNA and regulate renin production (PMID:12933794)
• HuR has a role in enhancing VHL-mediated p53 translation (PMID:14517280)
• HuR and MK2 have roles in regulating the expression of uPA and uPAR genes at the posttranscriptional level (PMID:14517288)
• Overexpression of HuR in bronchial epithelial cells significantly increases the expression and stability of eotaxin mRNA and protein. (PMID:14530362)
• HuR-regulated target mRNA expression contributes to colon cancer growth. (PMID:14562043)
• AUF1 p40, HuR, and the 3’UTR of the CTR mRNA transcript could be involved in posttranscriptional regulation of CTR mRNA expression. (PMID:14715706)
• Transportin-2 mediates nuclear import of HuR protein in vitro (PMID:14981248)
• an HuR target RNA motif and a general strategy for identifying target motifs for RNA-binding proteins (PMID:14981256)
• composition and fate (stability, translation) of HuR- and/or AUF1-containing ribonucleoprotein complexes depend on the target mRNA of interest, RNA-binding protein abundance, stress condition, and subcellular compartment (PMID:15257295)
• Overexpression of HuR in tumor tissue may be part of a regulatory pathway that controls the mRNA in breast cancer (PMID:15328200)
• Results point to importin alpha1 as a critical downstream target of AMP-activated protein kinase (AMPK) and key mediator of AMPK-triggered HuR nuclear import. (PMID:15342649)
• PGA2 stabilizes the p21 mRNA through an ERK-independent increase in cytoplasmic HuR levels and an ERK-dependent association of HuR with the p21 mRNA (PMID:15371446)
• IL-8 RNA from IL-1beta-stimulated cytoplasmic extract revealed a 20-fold greater association of transcript with the stabilizing factor HuR in breast csancer cells. (PMID:15514971)
• HuR contributes to regulating human vascular smooth muscle cell growth and homeostasis in pathologies associated with vascular smooth muscle proliferation (PMID:15824116)
• The function of HuR as a 5’-UTR-binding protein and dual-purpose translation repressor may be critical for the precise regulation of type I insulin-like growth factor receptor expression. (PMID:15914670)
• coordinated regulation of mRNA stability by HuR and AUF1 proteins contributes to the observed increase in ATF3 expression following amino acid limitation (PMID:16109718)
• HuR is a key mediator of posttranscriptional regulation and expression of the SLC11A1 gene. (PMID:16135804)
• c-Yes 3’-UTR contains at least three newly identified adenine/uridine-rich elements (AREs) which are bound specifically by ARE-binding proteins HuR and AUF1. (PMID:16289864)
• HuR-mediated mRNA stabilization, stimulated by integrin engagement and controlled at the level of HuR nuclear export, is critically involved in T cell activation (PMID:16455966)
• the HuR-CRM1 axis affects the nucleocytoplasmic translocation of CD83 mRNA under regular physiological conditions (PMID:16484227)
• The mRNAs for GM-CSF and TNF-alpha - established ARE-containing targets for HuR-mediated regulation - were upregulated by LPL-mediated lipolysis in ECAP. (PMID:16494882)
• HUR maintains cytochrome c biosynthesis. (PMID:16581801)
• role for HuR in protecting kidney epithelia from injury during ischemic stress (PMID:16788138)
• Results describe the gene expression of tristetraprolin, T-cell intracellular antigen and Hu antigen R in synovial tissues from rheumatoid arthritis and osteoarthritis patients. (PMID:16820934)
• adenosine/uridine (AU)-rich element-binding protein HuR (Hu antigen R) interacts with the beta-F1-ATPase mRNA through an AU-rich sequence located to the 3’-UTR. (PMID:16890199)
• HuR critically contributes to cyclin E1 overexpression and its growth-promoting function in breast cancer cells. (PMID:16912169)
• IL-10 sensitivity to TNF depends on the ability of IL-10 to inhibit the expression and mRNA-stabilizing protein HuR and via IL-10 mediated repression of p38 mitogen-activated protein (MAP) kinase activation (PMID:16935932)
• Activation of NADPH oxidase and MAPK-signaling pathway contribute to HuR-mediated stabilization of TLR4 mRNA induced by LPS in human aortic smooth muscle cells (HASMCs). Stimulation of HASMCs with LPS increased the cytosolic HuR level in vitro. (PMID:16990552)
• The RNA-binding protein HuR regulates the stability and translation of target mRNAs, while no HuR mutations have been found in cancer, a link between HuR and malignant transformation has been suggested in cancers of the breast, colon, lung and ovary. (PMID:17132932)
• the signal sequences in APRIL that mediate its intracellular trafficking and provide evidence that this protein ligand of HuR is an important player in the post-transcriptional regulation of CD83 expression (PMID:17178712)
• HuR-dependent regulation of RNase-L enhances its antiviral activity, demonstrating the functional significance of this regulation (PMID:17237228)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	elavl1a	ENSDARG00000038695
danio_rerio	elavl1b	ENSDARG00000101744
mus_musculus	Elavl1	ENSMUSG00000040028
rattus_norvegicus	Elavl1	ENSRNOG00000001069

Paralogs (24): PABPC1 (ENSG00000070756), RBMS2 (ENSG00000076067), PABPC4 (ENSG00000090621), PABPC1L (ENSG00000101104), ELAVL2 (ENSG00000107105), RBM24 (ENSG00000112183), TARDBP (ENSG00000120948), HNRNPR (ENSG00000125944), RBM38 (ENSG00000132819), SYNCRIP (ENSG00000135316), SF3B4 (ENSG00000143368), RBMS3 (ENSG00000144642), PABPC3 (ENSG00000151846), RBMS1 (ENSG00000153250), RBM45 (ENSG00000155636), ELAVL4 (ENSG00000162374), PABPC5 (ENSG00000174740), PUF60 (ENSG00000179950), PABPC1L2B (ENSG00000184388), PABPC1L2A (ENSG00000186288), RBM34 (ENSG00000188739), ELAVL3 (ENSG00000196361), RBM14 (ENSG00000239306), PABPC4L (ENSG00000254535)

Protein

Protein identifiers

ELAV-like protein 1 — Q15717 (reviewed: Q15717)

Alternative names: Hu-antigen R

All UniProt accessions (3): Q15717, M0QZR9, M0R055

UniProt curated annotations — full annotation on UniProt →

Function. RNA-binding protein that binds to the 3’-UTR region of mRNAs and increases their stability. Involved in embryonic stem cell (ESC) differentiation: preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), stabilizing them, promoting ESC differentiation. Has also been shown to be capable of binding to m6A-containing mRNAs and contributes to MYC stability by binding to m6A-containing MYC mRNAs. Binds to poly-U elements and AU-rich elements (AREs) in the 3’-UTR of target mRNAs. Binds avidly to the AU-rich element in FOS and IL3/interleukin-3 mRNAs. In the case of the FOS AU-rich element, binds to a core element of 27 nucleotides that contain AUUUA, AUUUUA, and AUUUUUA motifs. Binds preferentially to the 5’-UUUU[AG]UUU-3’ motif in vitro. With ZNF385A, binds the 3’-UTR of p53/TP53 mRNA to control their nuclear export induced by CDKN2A. Hence, may regulate p53/TP53 expression and mediate in part the CDKN2A anti-proliferative activity. May also bind with ZNF385A the CCNB1 mRNA. Increases the stability of the leptin mRNA harboring an AU-rich element (ARE) in its 3’ UTR.

Subunit / interactions. Monomer and homodimer (in vitro). Interacts with ANP32A. Interacts with ZNF385A; the interaction is indirect and mRNA-dependent and may regulate p53/TP53 expression. Identified in a mRNP complex, at least composed of DHX9, DDX3X, ELAVL1, HNRNPU, IGF2BP1, ILF3, PABPC1, PCBP2, PTBP2, STAU1, STAU2, SYNCRIP and YBX1. Interacts with AGO1 and AGO2. Interacts with IGF2BP1; the interaction is enhanced by SEPIN14P20 peptide RBPR. Interacts with IGF2BP2 and IGF2BP3. Interacts with HNRNPL. Interacts with DHX36; this interaction occurs in a RNA-dependent manner. Interacts with ILF3; this interaction occurs in a RNA-dependent manner. Interacts with PLEKHN1. Interacts with SHFL; the interaction increases in presence of RNA. Interacts with YBX1; interaction recruits ELAVL1 on C5-methylcytosine (m5C)-containing mRNAs, thereby promoting mRNA stability. Interacts with FXR1.

Subcellular location. Cytoplasm. Nucleus. Stress granule. P-body.

Tissue specificity. Ubiquitous. Detected in brain, liver, thymus and muscle.

Post-translational modifications. Phosphorylated by MAPKAPK2. Phosphorylated by PRKCD. Methylated at Arg-217 by CARM1 in macrophages in response to LPS challenge.

Domain organisation. The first RRM (RNA recognition motif) domain is essential for binding to AU-rich elements.

Similarity. Belongs to the RRM elav family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q15717-1	1	yes
Q15717-2	2

RefSeq proteins (1): NP_001410* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR002343	Hud_Sxl_RNA	Family
IPR006548	ELAD_HU_SF	Family
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034996	HuR_RRM2	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily

Pfam: PF00076

UniProt features (47 total): strand 13, modified residue 11, helix 9, mutagenesis site 3, domain 3, turn 3, initiator methionine 1, chain 1, cross-link 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
6GD3	X-RAY DIFFRACTION	1.35
4FXV	X-RAY DIFFRACTION	1.9
6GC5	X-RAY DIFFRACTION	1.9
6GD2	X-RAY DIFFRACTION	1.9
3HI9	X-RAY DIFFRACTION	2
4ED5	X-RAY DIFFRACTION	2
6G2K	X-RAY DIFFRACTION	2.01
6GD1	X-RAY DIFFRACTION	2.01
4EGL	X-RAY DIFFRACTION	2.9
9W2F	ELECTRON MICROSCOPY	3.4
5SZW	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15717-F1	80.13	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (12): 202, 206, 217, 217, 221, 318, 191, 2, 2, 100, 158, 197

Mutagenesis-validated functional residues (3):

Position	Phenotype
158	decreases phosphorylation by prkcd.
221	decreases phosphorylation by prkcd. nearly abolishes phosphorylation by prkcd and translocation from the nucleus into th
318	decreases phosphorylation by prkcd. nearly abolishes phosphorylation by prkcd and translocation from the nucleus into th

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-450520	HuR (ELAVL1) binds and stabilizes mRNA
R-HSA-9918481	Dengue Virus-Host Interactions

MSigDB gene sets: 362 (showing top): ATF_B, GOBP_REGULATION_OF_AUTOPHAGY, PAX4_01, GOBP_VACUOLE_ORGANIZATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, TTTGTAG_MIR520D, GOBP_REGULATION_OF_SUPEROXIDE_ANION_GENERATION, GOBP_3_UTR_MEDIATED_MRNA_STABILIZATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_SUPEROXIDE_METABOLIC_PROCESS, DARWICHE_SKIN_TUMOR_PROMOTER_UP, MITSIADES_RESPONSE_TO_APLIDIN_DN, DARWICHE_PAPILLOMA_RISK_LOW_UP, DARWICHE_PAPILLOMA_RISK_HIGH_UP

GO Biological Process (16): lncRNA-mediated post-transcriptional gene silencing (GO:0000512), protein import into nucleus (GO:0006606), cell population proliferation (GO:0008283), response to glucose (GO:0009749), positive regulation of autophagy (GO:0010508), positive regulation of superoxide anion generation (GO:0032930), positive regulation of translation (GO:0045727), positive regulation of autophagosome size (GO:0045772), mRNA stabilization (GO:0048255), protein homooligomerization (GO:0051260), negative regulation of miRNA-mediated gene silencing (GO:0060965), mRNA destabilization (GO:0061157), 3’-UTR-mediated mRNA stabilization (GO:0070935), regulation of stem cell population maintenance (GO:2000036), post-transcriptional gene silencing (GO:0016441), regulation of mRNA stability (GO:0043488)

GO Molecular Function (11): RNA binding (GO:0003723), double-stranded RNA binding (GO:0003725), mRNA binding (GO:0003729), mRNA 3’-UTR binding (GO:0003730), protein kinase binding (GO:0019901), miRNA binding (GO:0035198), mRNA 3’-UTR AU-rich region binding (GO:0035925), protein homodimerization activity (GO:0042803), lncRNA binding (GO:0106222), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (13): P-body (GO:0000932), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), cytosol (GO:0005829), cytoplasmic stress granule (GO:0010494), membrane (GO:0016020), sarcoplasm (GO:0016528), cytoplasmic vesicle (GO:0031410), postsynapse (GO:0098794), glutamatergic synapse (GO:0098978), ribonucleoprotein complex (GO:1990904)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Regulation of mRNA stability by proteins that bind AU-rich elements	1
Dengue Virus Infection	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
cytoplasm	4
RNA binding	3
regulation of mRNA stability	2
negative regulation of gene expression	2
binding	2
cytoplasmic ribonucleoprotein granule	2
intracellular membrane-bounded organelle	2
synapse	2
regulatory ncRNA-mediated post-transcriptional gene silencing	1
intracellular protein transport	1
protein localization to nucleus	1
import into nucleus	1
establishment of protein localization to organelle	1
cellular process	1
response to hexose	1
autophagy	1
positive regulation of catabolic process	1
regulation of autophagy	1
regulation of superoxide anion generation	1
superoxide anion generation	1
positive regulation of reactive oxygen species metabolic process	1
translation	1
regulation of translation	1
positive regulation of gene expression	1
positive regulation of protein metabolic process	1
regulation of autophagosome size	1
RNA stabilization	1
negative regulation of mRNA catabolic process	1
protein complex oligomerization	1
miRNA-mediated post-transcriptional gene silencing	1
regulation of miRNA-mediated gene silencing	1
negative regulation of post-transcriptional gene silencing by regulatory ncRNA	1
RNA destabilization	1
positive regulation of mRNA catabolic process	1
mRNA stabilization	1
stem cell population maintenance	1
regulation of developmental process	1
regulation of multicellular organismal process	1
post-transcriptional regulation of gene expression	1

Protein interactions and networks

STRING

3760 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ELAVL1	AGO2	Q9UKV8	993
ELAVL1	UFC1	Q9Y3C8	987
ELAVL1	PABPN1	Q86U42	978
ELAVL1	TIA1	P31483	968
ELAVL1	TIAL1	Q01085	945
ELAVL1	IGF2BP1	Q9NZI8	943
ELAVL1	ANP32A	P39687	904
ELAVL1	G3BP1	Q13283	883
ELAVL1	HNRNPD	P07029	876
ELAVL1	IGF2BP3	O00425	860
ELAVL1	HNRNPC	P07910	852
ELAVL1	PABPC1	P11940	848
ELAVL1	ZFP36	P26651	837
ELAVL1	YBX1	P16990	835
ELAVL1	FMR1	Q06787	833

IntAct

272 interactions, top by confidence:

A	B	Type	Score
PIK3CA	PIK3R2	psi-mi:“MI:0914”(association)	0.900
HNRNPC	KPNA3	psi-mi:“MI:0914”(association)	0.850
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
ATXN1	ELAVL1	psi-mi:“MI:0915”(physical association)	0.670
IGF2BP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
NCBP1	KPNA3	psi-mi:“MI:0914”(association)	0.640
TARDBP	ELAVL1	psi-mi:“MI:0915”(physical association)	0.610
IGF2BP1	SYNCRIP	psi-mi:“MI:0914”(association)	0.580
IGF2BP1	ELAVL1	psi-mi:“MI:0403”(colocalization)	0.580
ELAVL1	SDCBP	psi-mi:“MI:0915”(physical association)	0.560
HNRNPD	HNRNPDL	psi-mi:“MI:0914”(association)	0.560
TUBB3	POTEF	psi-mi:“MI:0914”(association)	0.530
DLD	PDHB	psi-mi:“MI:0914”(association)	0.530
N	HNRNPDL	psi-mi:“MI:0914”(association)	0.530

BioGRID (2346): HDAC6 (Affinity Capture-Western), ELAVL1 (Affinity Capture-Western), ELAVL1 (Affinity Capture-Western), TRAF3IP2 (Affinity Capture-Western), ELAVL1 (Affinity Capture-Western), ELAVL1 (Affinity Capture-Western), SDCBP (Two-hybrid), ELAVL1 (Affinity Capture-MS), ELAVL1 (Affinity Capture-MS), ELAVL1 (Affinity Capture-MS), ELAVL1 (Affinity Capture-MS), ELAVL1 (Affinity Capture-MS), ELAVL1 (Affinity Capture-MS), ELAVL1 (Affinity Capture-MS), ELAVL1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IEW8, A4QNI8, B5DF91, O01671, O09032, O17310, O61374, O64380, O95758, O97018, P16914, P19339, P26378, P26599, P42731, P70372, P86049, Q12926, Q14576, Q15717, Q1JQ73, Q24668, Q28FX0, Q28GD4, Q29099, Q5R9H4, Q5R9Z6, Q5U259, Q5YD48, Q60899, Q60900, Q61701, Q6DEY7, Q6GLB5, Q6GR16, Q6YZW2, Q7SZT7, Q8CH84, Q8GZ26, Q8LFS6

Diamond homologs: A0A0R4IEW8, A4QNI8, A8NS61, A8WLV5, B3M3R5, B3NGA1, B4HUE4, B4IX08, B4KX02, B4LFQ9, B4MM23, B4PIS2, B4QRJ0, B5DF91, B8BCZ8, O01671, O04425, O09032, O17310, O61374, O75821, O89086, O97018, P16914, P19339, P19683, P23241, P26378, P28644, P29558, P49310, P60824, P60825, P60826, P70372, P98179, Q04836, Q12926, Q14011, Q14498

SIGNOR signaling

12 interactions.

A	Effect	B	Mechanism
PRKCD	up-regulates	ELAVL1	phosphorylation
MAPKAPK2	up-regulates	ELAVL1	phosphorylation
MAPK14	up-regulates	ELAVL1	phosphorylation
ELAVL1	“up-regulates quantity”	ADAM10	“post transcriptional regulation”
CHUK	“down-regulates quantity by destabilization”	ELAVL1	phosphorylation
CHEK2	“up-regulates activity”	ELAVL1	phosphorylation
CHEK2	“down-regulates activity”	ELAVL1	phosphorylation
MAPK15	“down-regulates activity”	ELAVL1	phosphorylation
CDK1	“down-regulates activity”	ELAVL1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 170 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA Polyadenylation	18	13.1×	1e-12
Processing of Capped Intron-Containing Pre-mRNA	15	10.2×	4e-09
mRNA Splicing - Major Pathway	18	8.1×	2e-09
mRNA Splicing	8	7.3×	2e-03
Macroautophagy	7	6.7×	6e-03
Dengue Virus-Host Interactions	15	5.7×	1e-05
Metabolism of RNA	11	3.8×	9e-03
Viral Infection Pathways	14	3.6×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of cytoplasmic translation	5	32.4×	5e-05
alternative mRNA splicing, via spliceosome	5	22.0×	3e-04
translational initiation	6	14.1×	4e-04
RNA processing	9	12.9×	8e-06
regulation of alternative mRNA splicing, via spliceosome	8	12.8×	4e-05
mitophagy	6	12.5×	8e-04
mRNA stabilization	5	12.0×	4e-03
intrinsic apoptotic signaling pathway	5	11.7×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

24 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	13
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1475 predictions. Top by Δscore:

Variant	Effect	Δscore
19:7963804:GAACC:G	acceptor_loss	1.0000
19:7963805:AACC:A	acceptor_loss	1.0000
19:7963806:ACCT:A	acceptor_loss	1.0000
19:7963808:C:A	acceptor_loss	1.0000
19:7963809:T:A	acceptor_loss	1.0000
19:7973719:TGGTA:T	donor_loss	1.0000
19:7973720:GGTAC:G	donor_loss	1.0000
19:7973721:GTAC:G	donor_loss	1.0000
19:7973722:TA:T	donor_loss	1.0000
19:7973723:A:T	donor_loss	1.0000
19:7973724:CCTGT:C	donor_loss	1.0000
19:7981081:A:AT	donor_loss	1.0000
19:7981183:TGTCC:T	acceptor_gain	1.0000
19:7981184:GTCC:G	acceptor_gain	1.0000
19:7981185:TCCT:T	acceptor_gain	1.0000
19:7981186:CCTG:C	acceptor_gain	1.0000
19:7981187:C:A	acceptor_loss	1.0000
19:7981188:T:C	acceptor_loss	1.0000
19:7981189:G:C	acceptor_gain	1.0000
19:7991682:T:TA	donor_gain	1.0000
19:7991714:AT:A	donor_gain	1.0000
19:7991827:AAAAT:A	acceptor_gain	1.0000
19:7991828:AAAT:A	acceptor_gain	1.0000
19:7991829:AAT:A	acceptor_gain	1.0000
19:7991830:AT:A	acceptor_gain	1.0000
19:7991830:ATCT:A	acceptor_loss	1.0000
19:7991831:TCT:T	acceptor_loss	1.0000
19:7991832:C:CC	acceptor_gain	1.0000
19:7991832:C:CG	acceptor_loss	1.0000
19:7963808:C:CC	acceptor_gain	0.9900

AlphaMissense

2165 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:7963504:T:A	K320N	1.000
19:7963504:T:G	K320N	1.000
19:7963505:T:A	K320I	1.000
19:7963506:T:C	K320E	1.000
19:7963507:G:C	F319L	1.000
19:7963507:G:T	F319L	1.000
19:7963508:A:G	F319S	1.000
19:7963509:A:G	F319L	1.000
19:7963512:A:G	S318P	1.000
19:7963514:A:T	V317D	1.000
19:7963520:A:G	L315S	1.000
19:7963550:A:G	L305P	1.000
19:7963562:G:T	A301D	1.000
19:7963563:C:G	A301P	1.000
19:7963569:C:G	A299P	1.000
19:7963571:G:T	A298D	1.000
19:7963572:C:G	A298P	1.000
19:7963588:C:A	M292I	1.000
19:7963588:C:G	M292I	1.000
19:7963588:C:T	M292I	1.000
19:7963595:A:T	V290E	1.000
19:7963596:C:T	V290M	1.000
19:7963597:A:C	F289L	1.000
19:7963597:A:T	F289L	1.000
19:7963598:A:C	F289C	1.000
19:7963598:A:G	F289S	1.000
19:7963599:A:C	F289V	1.000
19:7963599:A:G	F289L	1.000
19:7963599:A:T	F289I	1.000
19:7963601:C:A	G288V	1.000

dbSNP variants (sampled 300 via entrez): RS1000036976 (19:7994702 C>T), RS1000041193 (19:7958792 T>C), RS1000089472 (19:7996163 A>C,G), RS1000112037 (19:7983860 G>A), RS1000213826 (19:8000873 G>A), RS1000268263 (19:7988591 G>A), RS1000290086 (19:7958711 C>T), RS1000291745 (19:8005709 C>A,G,T), RS1000315850 (19:8000449 C>T), RS1000320999 (19:7988407 C>T), RS1000323938 (19:8005827 C>A,T), RS1000345155 (19:7959181 G>A,T), RS1000380716 (19:7989216 C>T), RS1000398803 (19:7983538 G>A), RS1000469084 (19:7964668 C>A)

Disease associations

OMIM: gene MIM:603466 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1250379 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 74,559 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL50	QUERCETIN	3	74,559

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

12 measured of 12 human assays (12 total across all organisms); most potent 12 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
cid_5992379	IC50	2700 nM
2-keto-3-pyridazin-3-yl-propionic acid ethyl ester	IC50	4600 nM
cid_3034178	IC50	14700 nM
cid_247668	IC50	16700 nM
cid_374010	IC50	17400 nM
cid_83851	IC50	21700 nM
3,5-bis(2,5-dioxo-1-pyrrolyl)benzoic acid	IC50	26900 nM
5-Amino-2-p-toluidinobenzenesulfonic acid	IC50	41000 nM
6-[(8-chloro-4-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzene]amido}-2-oxo-2H-chromen-7-yl)oxy]-5-hydroxy-3-methoxy-2,2-dimethyloxan-4-yl 5-methyl-1H-pyrrole-2-carboxylate	IC50	41900 nM
6-penta-1,3-diynyl-2-pyranone	IC50	44400 nM
MLS002707303	IC50	69600 nM
1-hydroxy-N-(3-nitrophenyl)-2-naphthalenecarboxamide	IC50	97400 nM

ChEMBL bioactivities

47 potent at pChembl≥5 of 58 total, top 45 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
11.00	Kd	0.01	nM	DEHYDROMUTACTIN
10.00	Kd	0.1	nM	CHEMBL1240928
10.00	Kd	0.1	nM	DEHYDROMUTACTIN
8.22	Kd	6	nM	DEHYDROMUTACTIN
8.05	Kd	9	nM	DEHYDROMUTACTIN
7.97	Kd	10.69	nM	CHEMBL3752910
7.97	ED50	10.69	nM	CHEMBL3752910
7.89	Ki	12.8	nM	CHEMBL4075458
7.85	Kd	14	nM	CHEMBL1240928
7.82	Ki	15	nM	CHEMBL4064932
7.39	Ki	41	nM	CHEMBL4095060
7.32	Ki	48	nM	CHEMBL4100171
7.30	Ki	50	nM	DIHYDROTANSHINONE I
7.26	Ki	55	nM	CHEMBL4105230
7.25	Ki	56	nM	CHEMBL4073526
7.17	IC50	68	nM	DIHYDROTANSHINONE I
7.09	Ki	81	nM	CHEMBL4094161
7.07	Kd	85	nM	OKICENONE
7.05	Kd	90	nM	OKICENONE
6.83	IC50	149	nM	DIHYDROTANSHINONE I
6.64	Kd	230	nM	CHEMBL1240928
6.46	Ki	350	nM	CHEMBL1499653
6.42	IC50	380	nM	CHEMBL4061748
6.38	Kd	420	nM	CHEMBL1240928
6.24	Ki	570	nM	CHEMBL1522581
6.23	Ki	590	nM	CHEMBL1330249
6.10	Ki	800	nM	CHEMBL1390568
5.98	Ki	1050	nM	CHEMBL1309685
5.96	Ki	1100	nM	CHEMBL1398194
5.85	IC50	1400	nM	QUERCETIN
5.62	IC50	2400	nM	CHEMBL1499653
5.47	Ki	3400	nM	CHEMBL1499653
5.43	IC50	3700	nM	CHEMBL1522581
5.40	IC50	4000	nM	CHEMBL1330249
5.35	Kd	4500	nM	CHEMBL4075458
5.34	Ki	4600	nM	CHEMBL1522581
5.29	Ki	5100	nM	CHEMBL1330249
5.29	IC50	5100	nM	CHEMBL1390568
5.21	IC50	6210	nM	CHEMBL4095140
5.19	Ki	6500	nM	CHEMBL1390568
5.18	IC50	6600	nM	CHEMBL1309685
5.17	IC50	6700	nM	CHEMBL1398194
5.16	Ki	6900	nM	CHEMBL1309685
5.14	Ki	7300	nM	CHEMBL1398194
5.09	IC50	8200	nM	CHEMBL1499653

PubChem BioAssay actives

46 with measured affinity, of 126 total; 21 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
6-(4,5-dihydroxy-2-methylnaphthalen-1-yl)-4-hydroxypyran-2-one	507005: Inhibition of recombinant full length HuR assessed as protein dimerization with TMR-labeled A/U-rich element of COX2 by confocal fluctuation spectroscopy	kd	<0.0001	uM
5,8-dihydroxy-3-methyl-9H-benzo[f][2]benzofuran-4-one	507002: Inhibition of recombinant HuR RRM1/RRM2 domain assessed as protein dimerization with TMR-labeled A/U-rich element of TNFalpha by confocal fluctuation spectroscopy	kd	0.0001	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148314: Binding affinity to human ELAVL1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0107	uM
1-(benzenesulfonyl)-3-phenylindole-4,5-dione	1489663: Binding affinity to human full length recombinant His-tagged HuR expressed in Escherichia coli Rosetta DH5alpha assessed as inhibition of interaction with single-strand Bi-AU RNA probe by AlphaScreen assay	ki	0.0128	uM
1-(benzenesulfonyl)-7-(4-methoxyphenyl)sulfanyl-3-phenylindole-4,5-dione	1489663: Binding affinity to human full length recombinant His-tagged HuR expressed in Escherichia coli Rosetta DH5alpha assessed as inhibition of interaction with single-strand Bi-AU RNA probe by AlphaScreen assay	ki	0.0150	uM
1-(benzenesulfonyl)-7-(4-methoxyphenyl)-3-phenylindole-4,5-dione	1489663: Binding affinity to human full length recombinant His-tagged HuR expressed in Escherichia coli Rosetta DH5alpha assessed as inhibition of interaction with single-strand Bi-AU RNA probe by AlphaScreen assay	ki	0.0410	uM
1-(4-fluorophenyl)sulfonyl-3-phenylindole-4,5-dione	1489663: Binding affinity to human full length recombinant His-tagged HuR expressed in Escherichia coli Rosetta DH5alpha assessed as inhibition of interaction with single-strand Bi-AU RNA probe by AlphaScreen assay	ki	0.0480	uM
(1R)-1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione	1489663: Binding affinity to human full length recombinant His-tagged HuR expressed in Escherichia coli Rosetta DH5alpha assessed as inhibition of interaction with single-strand Bi-AU RNA probe by AlphaScreen assay	ki	0.0500	uM
1-(benzenesulfonyl)-7-(3-methoxyphenyl)-3-phenylindole-4,5-dione	1489663: Binding affinity to human full length recombinant His-tagged HuR expressed in Escherichia coli Rosetta DH5alpha assessed as inhibition of interaction with single-strand Bi-AU RNA probe by AlphaScreen assay	ki	0.0550	uM
1-methylsulfonyl-3-phenylindole-4,5-dione	1489663: Binding affinity to human full length recombinant His-tagged HuR expressed in Escherichia coli Rosetta DH5alpha assessed as inhibition of interaction with single-strand Bi-AU RNA probe by AlphaScreen assay	ki	0.0560	uM
N-[4-(4,5-dioxo-3-phenylindol-1-yl)sulfonylphenyl]acetamide	1489663: Binding affinity to human full length recombinant His-tagged HuR expressed in Escherichia coli Rosetta DH5alpha assessed as inhibition of interaction with single-strand Bi-AU RNA probe by AlphaScreen assay	ki	0.0810	uM
4,6,9-trihydroxy-8-methyl-3,4-dihydro-2H-anthracen-1-one	507008: Binding affinity to recombinant full length HuR assessed as protein dimerization with TMR-labeled A/U-rich element of IL-2 by confocal fluctuation spectroscopy	kd	0.0850	uM
5,7-dimethoxy-8-[1-(4-methoxyphenyl)-3-oxo-3-pyrrolidin-1-ylpropyl]-4-phenylchromen-2-one	1450469: Inhibition of ELAV1 (unknown origin)-ARE sequence of Mushashi1 transcript complex formation after 2 hrs by fluorescence polarization assay	ki	0.3500	uM
2-amino-6-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]sulfanyl-4-[4-(phenoxymethyl)phenyl]pyridine-3,5-dicarbonitrile	1450466: Inhibition of ELAV1 (unknown origin)-ARE TNFalpha complex formation after 20 mins by liquid scintillation counting method	ic50	0.3800	uM
3-(5,7-dimethoxy-2-oxo-4-phenylchromen-8-yl)-N,N-diethyl-3-(4-methoxyphenyl)propanamide	1450469: Inhibition of ELAV1 (unknown origin)-ARE sequence of Mushashi1 transcript complex formation after 2 hrs by fluorescence polarization assay	ki	0.5700	uM
3-(5,7-dimethoxy-2-oxo-4-phenylchromen-8-yl)-N,N-diethyl-3-(3,4,5-trimethoxyphenyl)propanamide	1450469: Inhibition of ELAV1 (unknown origin)-ARE sequence of Mushashi1 transcript complex formation after 2 hrs by fluorescence polarization assay	ki	0.5900	uM
5,7-dimethoxy-8-[1-(4-methoxyphenyl)-3-morpholin-4-yl-3-oxopropyl]-4-phenylchromen-2-one	1450469: Inhibition of ELAV1 (unknown origin)-ARE sequence of Mushashi1 transcript complex formation after 2 hrs by fluorescence polarization assay	ki	0.8000	uM
8-[1-(1,3-benzodioxol-5-yl)-3-oxo-3-pyrrolidin-1-ylpropyl]-5,7-dimethoxy-4-phenylchromen-2-one	1450469: Inhibition of ELAV1 (unknown origin)-ARE sequence of Mushashi1 transcript complex formation after 2 hrs by fluorescence polarization assay	ki	1.0500	uM
5,7-dimethoxy-8-[3-oxo-3-pyrrolidin-1-yl-1-(3,4,5-trimethoxyphenyl)propyl]-4-phenylchromen-2-one	1450469: Inhibition of ELAV1 (unknown origin)-ARE sequence of Mushashi1 transcript complex formation after 2 hrs by fluorescence polarization assay	ki	1.1000	uM
Quercetin	1450466: Inhibition of ELAV1 (unknown origin)-ARE TNFalpha complex formation after 20 mins by liquid scintillation counting method	ic50	1.4000	uM
2-[[6-amino-3,5-dicyano-4-(4-methoxyphenyl)-2-pyridinyl]sulfanyl]-N-(4-chlorophenyl)acetamide	1450466: Inhibition of ELAV1 (unknown origin)-ARE TNFalpha complex formation after 20 mins by liquid scintillation counting method	ic50	6.2100	uM

CTD chemical–gene interactions

84 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases degradation, decreases expression, increases expression, affects binding, increases phosphorylation (+4 more)	6
trichostatin A	affects cotreatment, affects localization, decreases expression	4
Valproic Acid	affects expression, decreases expression, increases expression	4
deoxynivalenol	affects cotreatment, decreases degradation, affects localization, increases activity, increases reaction (+5 more)	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
Antimycin A	decreases reaction, decreases expression, decreases localization, affects binding	2
Tretinoin	decreases expression	2
1-Methyl-4-phenylpyridinium	increases expression, affects reaction, increases cleavage, increases secretion, increases reaction	2
GLX351322	decreases expression, decreases reaction	1
quinone	decreases expression	1
2,4,6-tribromophenol	increases expression	1
triphenyl phosphate	affects expression	1
4-biphenylamine	affects expression, affects reaction, affects lipidation	1
decabromobiphenyl ether	increases expression	1
2-butenal	decreases expression	1
tetrabromobisphenol A	increases expression	1
3-methyladenine	decreases expression, decreases reaction, decreases stability	1
butylidenephthalide	decreases expression	1
AICA ribonucleotide	affects binding, decreases reaction, decreases localization	1
hydroquinone	decreases expression, decreases reaction, increases degradation, increases reaction	1
cyclic 3’,5’-uridine monophosphate	affects binding	1
epigallocatechin gallate	increases expression	1
arsenic trichloride	increases reaction, affects binding	1
di-n-butylphosphoric acid	affects expression	1
1,2-bis(2-aminophenoxy)ethane N,N,N’,N’-tetraacetic acid acetoxymethyl ester	decreases reaction, increases phosphorylation	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
Go 6976	decreases reaction, increases phosphorylation	1
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	decreases stability, decreases expression, decreases reaction	1
deguelin	decreases expression	1

ChEMBL screening assays

54 unique, capped per target: 53 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1243881	Binding	Inhibition of recombinant HuR RRM1/RRM2 domain assessed as protein interaction with TMR-labeled A/U-rich element of IL-2 by confocal fluctuation spectroscopy	Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. — Nat Chem Biol
CHEMBL3562061	Functional	PubChem BioAssay. Identify HuR specific inhibitors. (Class of assay: confirmatory)	PubChem BioAssay data set

Cellosaurus cell lines

7 cell lines: 7 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B0YT	Abcam SW480 ELAVL1 KO	Cancer cell line	Male
CVCL_D7PA	Ubigene A-549 ELAVL1 KO	Cancer cell line	Male
CVCL_KT68	HeLa SilenciX HuR	Cancer cell line	Female
CVCL_SL83	HAP1 ELAVL1 (-) 1	Cancer cell line	Male
CVCL_SL84	HAP1 ELAVL1 (-) 2	Cancer cell line	Male
CVCL_SL85	HAP1 ELAVL1 (-) 3	Cancer cell line	Male
CVCL_SL86	HAP1 ELAVL1 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.